about
A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterolFamilial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis SocietyDiagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and childrenMolecular diagnosis of hypobetalipoproteinemia: an ENID reviewA targeted apoB38.9 mutation in mice is associated with reduced hepatic cholesterol synthesis and enhanced lipid peroxidationNovel LMF1 nonsense mutation in a patient with severe hypertriglyceridemiaLipid peroxidation, nitric oxide metabolites, and their ratio in a group of subjects with metabolic syndrome.Study of the correlations among some parameters of the oxidative status, gelatinases, and their inhibitors in a group of subjects with metabolic syndrome.Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society.Ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potencyThe polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management.Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia.Multiple food hypersensitivity as a cause of refractory chronic constipation in adults.Lipase maturation factor 1 is required for endothelial lipase activity.Identifying genetic risk variants for coronary heart disease in familial hypercholesterolemia: an extreme genetics approach.eNOS activation by HDL is impaired in genetic CETP deficiency.A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community.The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment.Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.The atrial natriuretic peptide genetic variant rs5068 is associated with a favorable cardiometabolic phenotype in a Mediterranean population.Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis.A novel APOB mutation identified by exome sequencing cosegregates with steatosis, liver cancer, and hypocholesterolemia.A novel component of the metabolic syndrome: the oxidative stress.Clinical utility of novel biomarkers for cardiovascular disease risk stratification.Beyond statins: new lipid lowering strategies to reduce cardiovascular risk.The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice.Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia.Homozygous familial hypobetalipoproteinemia: two novel mutations in the splicing sites of apolipoprotein B gene and review of the literature.The effect of ezetimibe on NAFLD.The pathophysiology of intestinal lipoprotein production.Prevalence of 'borderline' values of cardiovascular risk factors in the clinical practice of general medicine in Italy: results of the BORDERLINE study.C-reactive protein but not soluble CD40 ligand and homocysteine is associated to common atherosclerotic risk factors in a cohort of coronary artery disease patients.Obesity and the metabolic syndrome in a student cohort from Southern Italy.ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic-therapeutic pathway in Italy.FragClust and TestClust, two informatics tools for chemical structure hierarchical clustering analysis applied to lipidomics. The example of Alzheimer's disease.Low-density lipoproteins generated during an oral fat load in mild hypertriglyceridemic and healthy subjects are smaller, denser, and have an increased low-density lipoprotein receptor binding affinity.Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.Analysis of sterols by high-performance liquid chromatography/mass spectrometry combined with chemometrics.[ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Consensus document. Hypercholesterolemia and cardiovascular risk: diagnostic and therapeutic pathways in Italy].
P50
Q24336810-75FC3ED4-33C4-4CF7-9E29-385632A471CCQ27024882-9EDF8717-5BEF-4F07-8060-D21878F5328EQ28196268-59A83761-DAA0-4F9A-8C64-2003BD77E010Q28306392-C2385690-5A5C-4C83-A1A7-11B9B6BE153BQ28585589-C993BCD1-63A8-4D69-AA72-4151A15CE60DQ33644452-B548A6EB-8484-4319-826F-15F500ECC42CQ33765378-E009EC3C-B268-455E-91E6-A92FB1804AC9Q33999929-5E79F2D4-9070-4F00-B9A2-21D86110109DQ34071937-C2209F4F-4930-497A-ACAC-71AA0CE1394BQ34353742-0CE340A3-CFC2-454A-959E-265E719BC855Q34359967-5AFBAB89-1CC6-4D4F-A756-22EB60E1D8A8Q34453670-539C46D6-A7CE-4239-AB72-4316C3663E1CQ34517145-F005FF1B-8BEC-4EC9-A771-6CAC480792F6Q34955884-8DC1E209-2B79-49F0-81AB-8ED775AAF816Q35079924-19F1909E-77A5-4860-91EC-BEF104515291Q35168995-D203377B-D5C0-4ADF-8BF6-9822481243B1Q35283673-C6D79A31-C0BA-413D-9666-14EFF23A7B4CQ36069577-BAC8D2D3-C508-401D-9BEE-41FE539C75D3Q36076131-83C56FB6-FDE3-4FE3-BB68-0EB741B2C7DDQ36104706-319148E9-DE76-4F32-AB56-039EBE6233ABQ37106593-54C86EEB-E64B-4E4A-BEF2-66A0BFD9858EQ37305417-56EB4336-3BA5-4B66-9055-340EF28BB9A5Q37408477-E3629C67-EA86-4F20-9601-98343097206DQ37595771-322ACB66-E00B-4E36-9B27-C2963A3CDDEFQ38052852-488D58C7-7F3E-41FE-8CDE-2B566F78DF27Q38207925-9BD46BEE-7DC5-4050-BEED-B4256012D295Q38212766-41FDD2D8-0B79-4C35-877B-1B1EF475FF3EQ38254436-73099E25-B079-4563-9278-F27471717102Q38330970-95586BEB-222B-4EBA-A691-8BE0D6ACBB78Q38346999-26845F05-8704-4532-B6EE-CDAACF1B861EQ38410893-AE5483F9-FEB6-4EAC-8DB1-9C81E4C36BBEQ39722466-FB2ACD39-CFA2-4299-8AE0-7612B6B3AB95Q39949238-F4857FBD-61EF-4B2A-9C42-D90B607E4760Q39997562-A9423A45-4EF5-411B-AB9D-9AA82914F5A0Q40104818-E5061045-D553-47A5-A25F-59790B379028Q40121034-232A49B0-0C2A-4D44-B9C6-F15AA76EB1E9Q40231066-220F0C93-D536-4CFE-B148-009B60C910D8Q40241401-9716CB1D-DE82-41EB-BB4B-7C6A739AC85FQ40307360-9D43459F-6BB7-4F64-97EA-FC95560A3675Q40696596-4595971A-38A4-499D-930B-D7BDF1760746
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Maurizio Averna
@ast
Maurizio Averna
@en
Maurizio Averna
@es
Maurizio Averna
@nl
Maurizio Averna
@sl
type
label
Maurizio Averna
@ast
Maurizio Averna
@en
Maurizio Averna
@es
Maurizio Averna
@nl
Maurizio Averna
@sl
prefLabel
Maurizio Averna
@ast
Maurizio Averna
@en
Maurizio Averna
@es
Maurizio Averna
@nl
Maurizio Averna
@sl
P227
P101
P106
P1153
7005411173
P21
P214
21150083647414940269
P227
113701606X
P31
P496
0000-0003-3558-9209
P735
P7859
viaf-21150083647414940269